DiaSys Corporation (OTCBB: DYXC) a global healthcare products company, announced today that it has signed a new three-year distribution agreement with Galenica S.A., in Chile. The agreement guarantees minimum purchase orders of $1.01 million for the Company’s parasitology and urine sediment workstations and consumable products over the three-year period. Galenica S.A., which was founded in 1985, also represents Beckman Coulter and IRIS International.

"Our three year distribution agreement in Chile is another significant achievement in Latin America for DiaSys Corporation. We received a major commitment from the largest medical distributor of diagnostic products in Chile," said Gregory Witchel, Chief Executive Officer.

Jose Puig, Sales Manager Latin America stated, "This agreement in Chile provides DiaSys with a strong and growing market presence in Latin America for our parasitology and urine sediment product lines. We will extend our sales initiative throughout the territory during 2006."

DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test-kits to healthcare & veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary based in Wokingham, England and in Pacific Asia through its strategic business partner located in Guangzhou, China. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation. DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test-kits to healthcare & veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary based in Wokingham, England and in Pacific Asia through its strategic business partner located in Guangzhou, China. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation.

This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on Form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company.

Back